%0 Journal Article
%T ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers?
%A Nagasaka M
%A Ly CT
%A Ou SI
%J Med
%V 5
%N 7
%D 2024 Jul 12
%M 39002534
暂无%R 10.1016/j.medj.2024.05.010
%X The ALINA trial1 demonstrated that 2 years of adjuvant alectinib achieved statistically significantly improved 2-year overall and central nervous system (CNS) disease-free survival over platinum-doublet chemotherapy in resected early-stage (IB ≥ 4 cm to IIIA) ALK+ non-small cell lung cancer (NSCLC). Identifying early-stage ALK+ NSCLC patients (60% were never-smokers in the ALINA trial) may require low-dose computed tomography (LDCT) lung cancer screening in never-smokers.